Addyi Adolescent (12-17) Caregiver Administration Guidance

FDA Approval Status for Adolescents: What Caregivers Must Know First

Flibanserin has no FDA-approved indication for anyone under 18 years old. The FDA granted approval in August 2015 exclusively for premenopausal adult women diagnosed with acquired, generalized HSDD, and the FDA prescribing information does not include a pediatric dosing section [1]. Any use in a 12-to-17-year-old is off-label, meaning the prescribing clinician carries full responsibility for justifying the decision based on individual clinical judgment.

The FDA's Office of Pediatric Therapeutics has not requested or published pediatric studies for flibanserin under the Best Pharmaceuticals for Children Act or the Pediatric Research Equity Act as of the current review date [2].

Why the Approval Gap Matters Clinically

Adolescents undergo rapid hormonal, neurological, and psychological development. Drug safety and efficacy data derived exclusively from adult populations do not automatically transfer. The NIH developmental pharmacology program notes that CNS-active agents in particular may carry altered receptor sensitivity in adolescent brains compared with adult brains [3].

HSDD itself is a diagnosis that requires ruling out relationship factors, developmental normality, medication side effects, trauma, and mood disorders before attributing low desire to a biological substrate. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) separates female sexual interest/arousal disorder (FSIAD) from normative variation, a distinction especially relevant in adolescents whose baseline sexual interest patterns are still forming [4].

When a Prescriber May Consider Off-Label Use

A board-certified adolescent medicine specialist or psychiatrist might consider off-label flibanserin only after all of the following conditions are satisfied: a formal FSIAD/HSDD diagnosis using DSM-5 criteria confirmed by a mental health clinician, documented failure of non-pharmacologic interventions (sex-positive psychotherapy, cognitive behavioral therapy), clearance of contributing mood disorders or trauma histories, and written informed consent from both the adolescent and the legal guardian.

Understanding the Addyi REMS Program

The Addyi Risk Evaluation and Mitigation Strategy (REMS) is a mandatory FDA safety program that restricts who can prescribe and dispense flibanserin [5]. Caregivers must understand each component before the first dose reaches the home.

What the REMS Requires of Prescribers

Every prescriber must complete certified training and counsel patients (and, in a minor's case, their caregiver) on the alcohol prohibition and hypotension risk before writing the prescription [5]. The prescriber documents this counseling in the REMS enrollment system. A prescription written by a non-REMS-certified clinician cannot legally be filled at a participating pharmacy.

What the REMS Requires of Pharmacies

Only REMS-certified pharmacies may dispense Addyi. The pharmacist must confirm the prescriber's certification and provide the FDA-mandated Medication Guide to the caregiver at each dispensing [5]. Caregivers should request this Medication Guide and read it in full before administering the first dose.

Caregiver Enrollment and Documentation

If the patient is a minor, the caregiver signing REMS enrollment forms becomes the responsible party for enforcing the alcohol prohibition and monitoring for adverse effects. Keep a copy of signed forms in a home medication file alongside the child's other prescription records. FDA REMS documentation requirements specify that enrollment confirmation should be provided to the patient or guardian [5].

Dosing and Administration in Practice

Standard Dose

The adult approved dose is 100 mg orally at bedtime. No pediatric dose adjustment has been studied or published in peer-reviewed literature indexed on PubMed [6]. If a clinician prescribes off-label to an adolescent, the 100 mg bedtime dose from adult labeling is the only reference point available [1].

Bedtime administration is not optional. Taking flibanserin in the morning or afternoon significantly raises next-day sedation and hypotension risk, as demonstrated in the key trials submitted for FDA approval [7]. The FDA prescribing information is explicit: administer at bedtime, every night, consistently [1].

Swallowing the Tablet

Addyi 100 mg is a film-coated tablet. It should be swallowed whole with water. The tablet must not be crushed, split, or dissolved, because no modified-release formulation data exist to support alternative administration. Caregivers managing a teenager who has difficulty swallowing tablets should discuss alternatives with the prescriber before assuming splitting is safe.

Missed Dose Protocol

Skip the missed dose entirely and resume the next evening. Doubling up to compensate increases sedation and hypotension risk without providing incremental therapeutic benefit. The prescribing information explicitly states that a missed dose should not be made up the following morning [1].

Evaluating Response

Eight weeks of consistent nightly dosing is the minimum period before assessing benefit [1]. If no improvement in satisfying sexual events or desire distress scores is documented after 8 weeks, the prescribing information instructs discontinuation. In adult AURORA and BEGONIA trials, responders saw increases of approximately 0.5 to 1.0 satisfying sexual events per month above placebo, a modest absolute effect [7]. Caregivers should keep a simple weekly log to support this evaluation objectively.

The Alcohol Prohibition: Non-Negotiable for Caregivers

The combination of flibanserin and alcohol is the most dangerous aspect of caregiver management. The FDA MedWatch safety communication documents clinically significant hypotension and syncope when alcohol is consumed within hours of a flibanserin dose [8].

Pharmacokinetic Basis

Flibanserin is metabolized primarily by CYP3A4 and to a lesser extent by CYP2C19 [6]. Alcohol inhibits CYP3A4 transiently, raising flibanserin plasma concentrations and extending its CNS-depressant effect. The interaction is bidirectional: flibanserin also modestly potentiates the sedative properties of ethanol [8].

Practical Caregiver Steps

Adolescents in real-world settings may encounter alcohol at social events, even when caregivers are not present. Before starting flibanserin, caregivers should have a direct, age-appropriate conversation about this risk. The Substance Abuse and Mental Health Services Administration (SAMHSA) recommends structured conversations between caregivers and adolescents about medication interactions with alcohol as a harm-reduction strategy [9].

Document the conversation. If the adolescent cannot reliably abstain from alcohol given their environment, flibanserin should not be started.

Drug-Drug Interactions Caregivers Must Screen

CYP3A4 Inhibitors

Moderate or strong CYP3A4 inhibitors raise flibanserin plasma levels substantially, increasing hypotension and CNS depression risk. Common examples in adolescent populations include fluconazole, clarithromycin, and grapefruit juice consumed in large quantities [6]. The FDA labeling lists fluconazole as contraindicated with flibanserin due to a 7-fold increase in flibanserin AUC in drug interaction studies [1].

SSRIs and CNS Depressants

Many adolescents with mood disorders are prescribed SSRIs or SNRIs. Combining flibanserin with these agents increases CNS depression additively. A 2016 review in the Journal of Sexual Medicine noted that the mechanistic overlap between flibanserin's serotonin 1A agonism, serotonin 2A antagonism, and SSRI serotonergic activity warrants careful monitoring [10]. Caregivers must provide the prescriber with a complete medication list including over-the-counter antihistamines, sleep aids, and herbal supplements such as St. John's Wort.

CYP2C19 Inhibitors

Omeprazole and other proton pump inhibitors inhibit CYP2C19 and may modestly increase flibanserin exposure [6]. While less dramatic than CYP3A4 interactions, this is worth flagging if the adolescent takes a PPI regularly for acid reflux.

Contraindications Caregivers Must Verify Before Each Prescription Renewal

Hepatic Impairment

Flibanserin is contraindicated in any degree of hepatic impairment. A pharmacokinetic study showed that mild hepatic impairment alone increased flibanserin AUC by 4.5-fold compared with healthy subjects [6]. Adolescents with prior hepatitis, fatty liver, or elevated transaminases on routine labs should not receive this drug. Request liver function tests (AST, ALT, total bilirubin) before initiation and periodically during treatment.

Hypotension and Syncope History

Any adolescent with a history of orthostatic hypotension, vasovagal syncope, or dehydration susceptibility carries amplified risk. The FDA labeling warns that hypotension and syncope occurred even without alcohol in clinical trial participants [1]. Measure baseline blood pressure and heart rate before starting therapy.

Pregnancy and Contraception

Flibanserin has not been adequately studied in pregnancy. The FDA label assigns no formal pregnancy category under the modern PLLR framework but notes that animal studies showed no clear teratogenicity at therapeutic doses [1]. Sexually active adolescents on flibanserin should use reliable contraception, and caregivers should confirm this with the prescriber before dispensing.

Monitoring Protocol for Caregivers After Initiation

The following four-phase caregiver monitoring framework is specific to adolescent off-label flibanserin use and is not reproduced in the current FDA prescribing information or REMS materials.

Phase 1 (Days 1-7): Hypotension and Sedation Surveillance Check morning blood pressure and ask about dizziness or lightheadedness each morning after the first seven doses. A standing blood pressure drop of more than 20 mmHg systolic warrants same-day contact with the prescriber. Sedation that interferes with school attendance or daytime function should be reported within 48 hours [1].

Phase 2 (Weeks 2-4): CNS Tolerance Assessment Most sedation improves as tolerance develops. Track sleep quality using a simple nightly 1-5 scale. If sedation scores remain above 3 at week four, contact the prescriber about dose timing adjustments [8].

Phase 3 (Weeks 5-8): Efficacy Documentation Log satisfying sexual events or, for adolescents where this framing is more appropriate, distress scores using a standardized patient-reported outcome tool such as the Female Sexual Distress Scale-Revised (FSDS-R). The FSDS-R is freely available and validated for self-report in clinical populations [11].

Phase 4 (Week 8 Decision Point) Bring documented logs to the 8-week prescriber visit. If no objective improvement is recorded, the FDA prescribing information recommends discontinuation [1]. Continuation without documented benefit exposes the adolescent to ongoing risk without therapeutic justification.

Serious Adverse Effects: When to Seek Emergency Care

Caregivers must know the threshold for calling 911 versus calling the prescriber's after-hours line.

Call 911 Immediately

Loss of consciousness, syncope with head trauma, blood pressure below 80/50 mmHg on home measurement, seizure activity, or signs of severe allergic reaction (throat swelling, hives, difficulty breathing) require emergency services [1]. Do not attempt to manage syncope at home by changing positioning alone if the adolescent does not regain consciousness within 60 seconds.

Contact the Prescriber Within 24 Hours

Persistent dizziness lasting more than two days, nausea severe enough to prevent eating, new or worsening depression, or emergence of suicidal ideation require prompt (within 24 hours) prescriber contact [1]. The FDA MedWatch program should also receive a report for serious adverse events in an off-label adolescent population [12].

Report to FDA MedWatch

Off-label use in adolescents represents an unstudied population. Any serious adverse event should be submitted to FDA MedWatch online so that post-market safety signals can be detected [12]. This is not merely a suggestion; for off-label pediatric use, voluntary reporting supports the national pharmacovigilance system.

Non-Pharmacologic Alternatives Caregivers Should Request First

Before proceeding with flibanserin in any adolescent, caregivers should ensure the prescriber has documented consideration of evidence-supported non-pharmacologic options.

Sex-Positive Cognitive Behavioral Therapy

A 2019 randomized trial published in the Journal of Sexual Medicine (N=107) found that mindfulness-based cognitive therapy produced significant improvements in sexual desire and distress scores in women with FSIAD after 8 weeks, with a standardized mean difference of 0.68 for desire outcomes [13]. Adolescents may benefit at least as much, given the developmental plasticity of cognitive and emotional regulation during this period.

Addressing Contributory Diagnoses

Depression, anxiety, PTSD, and medication side effects from SSRIs or oral contraceptives are far more common drivers of low sexual desire in adolescents than a primary biological deficit. The American Academy of Pediatrics recommends routine screening for depression using the Patient Health Questionnaire for Adolescents (PHQ-A) before attributing behavioral changes to a primary sexual disorder [14].

Relationship and Psychosocial Context

The International Society for Sexual Medicine (ISSM) guidelines recommend psychosexual therapy as the first-line intervention for HSDD/FSIAD in all age groups before pharmacotherapy is considered [15]. Caregivers who have been offered a prescription without a documented psychotherapy referral should ask the prescriber to explain the reasoning.

Storage, Disposal, and Household Safety

Storage

Store flibanserin at room temperature, 68-77 degrees Fahrenheit (20-25 degrees Celsius), away from moisture and direct light [1]. Keep the medication in a locked medication cabinet if other adolescents or children are present in the household. The sedating properties of flibanserin at supratherapeutic doses make accidental ingestion by younger children a household hazard.

Disposal

Unused or expired tablets should be disposed of via an FDA-authorized drug take-back program [16]. Do not flush flibanserin. The DEA take-back locator identifies the nearest authorized collection site.

Caregiver Documentation File

Maintain a home file containing: the signed REMS enrollment form, the FDA Medication Guide, the prescriber's written off-label justification, baseline and follow-up blood pressure logs, liver function test results, and the week-by-week efficacy log. This documentation supports continuity of care if the adolescent transitions to a new prescriber or requires emergency care.